
Kyoto University Innovation Capital
Description
Kyoto University Innovation Capital (KUIK) is a venture capital firm established in December 2014, wholly owned by Kyoto University. Its primary mission is to facilitate the commercialization of research outcomes from Kyoto University, aiming to generate new industries and contribute to societal advancement. KUIK serves as a crucial bridge between academic innovation and market application, providing capital and strategic support to promising ventures.
KUIK's investment strategy is broad, targeting ventures that leverage the extensive research capabilities of Kyoto University. Its focus areas span critical sectors including Life Science (e.g., drug discovery, regenerative medicine, digital health), Information and Communication Technology (e.g., AI, IoT, robotics, quantum computing), and Environment and Energy (e.g., new materials, renewable energy, carbon neutrality). Additionally, KUIK also explores opportunities in other emerging fields such as agriculture, food technology, and space. The firm invests across various stages, from seed and early-stage companies requiring initial capital to growth-stage enterprises seeking further expansion.
The firm manages significant capital through its dedicated funds. The KUIK 1st Fund, established in 2015, had a total commitment of ¥16.0 billion, followed by the KUIK 2nd Fund, launched in 2020, with ¥18.0 billion. KUIK typically provides initial investments ranging from approximately $64,516 to $3,225,806 per company, reflecting its commitment to supporting ventures from their foundational stages through to significant growth. This flexible check size allows KUIK to adapt to the varying capital needs of its diverse portfolio companies, reinforcing its role in nurturing university-born innovations into successful commercial entities.
Investor Profile
Kyoto University Innovation Capital has backed more than 21 startups, with 12 new investments in the last 12 months alone. The firm has led 1 rounds, about 5% of its total and boasts 2 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Seed, Series A, Series Unknown rounds (top funding stages).
- Majority of deals are located in Japan, Taiwan, United States.
- Strong thematic focus on Biotechnology, Health Care, Medical.
- Led 1 rounds in the past year.
- Typical check size: $64.5K – $3.2M.
Stage Focus
- Seed (33%)
- Series A (29%)
- Series Unknown (19%)
- Series B (19%)
Country Focus
- Japan (90%)
- Taiwan (5%)
- United States (5%)
Industry Focus
- Biotechnology
- Health Care
- Medical
- Manufacturing
- Pharmaceutical
- Information Technology
- Rental
- Natural Language Processing
- Therapeutics
- Clinical Trials
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.